QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

BioAtla Stock Price, News & Analysis (NASDAQ:BCAB)

$1.37
-0.40 (-22.60%)
(As of 12/4/2023 ET)
Compare
Today's Range
$1.35
$1.78
50-Day Range
$1.27
$1.98
52-Week Range
$1.24
$10.83
Volume
1.78 million shs
Average Volume
501,843 shs
Market Capitalization
$65.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.80

BioAtla MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
980.3% Upside
$14.80 Price Target
Short Interest
Bearish
8.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of BioAtla in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$5,080 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.75) to ($2.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

343rd out of 952 stocks

Biological Products, Except Diagnostic Industry

55th out of 155 stocks


BCAB stock logo

About BioAtla Stock (NASDAQ:BCAB)

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BCAB Stock Price History

BCAB Stock News Headlines

BCAB, DUNE and CDT among mid-day movers
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
BioAtla Inc Ordinary Shares BCAB
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
BioAtla Inc Registered Shs hosts conference call for investors
Analyst Ratings for BioAtla
H.C. Wainwright Reaffirms Their Buy Rating on BioAtla (BCAB)
See More Headlines
Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCAB
Fax
N/A
Employees
66
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.80
High Stock Price Target
$25.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+980.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-106,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$3.79 per share

Miscellaneous

Free Float
43,919,000
Market Cap
$65.68 million
Optionable
Not Optionable
Beta
0.69
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives















BCAB Stock Analysis - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares.
View BCAB analyst ratings
or view top-rated stocks.

What is BioAtla's stock price target for 2024?

5 Wall Street analysts have issued 12 month target prices for BioAtla's shares. Their BCAB share price targets range from $10.00 to $25.00. On average, they anticipate the company's share price to reach $14.80 in the next year. This suggests a possible upside of 980.3% from the stock's current price.
View analysts price targets for BCAB
or view top-rated stocks among Wall Street analysts.

How have BCAB shares performed in 2023?

BioAtla's stock was trading at $8.25 on January 1st, 2023. Since then, BCAB stock has decreased by 83.4% and is now trading at $1.37.
View the best growth stocks for 2023 here
.

When is BioAtla's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our BCAB earnings forecast
.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) announced its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.07.

What ETF holds BioAtla's stock ?

Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio.

When did BioAtla IPO?

(BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO.

Who are BioAtla's major shareholders?

BioAtla's stock is owned by many different retail and institutional investors. Top institutional shareholders include Adage Capital Partners GP L.L.C. (3.76%), Vontobel Holding Ltd. (1.50%), Sectoral Asset Management Inc. (1.48%), Vivo Capital LLC (1.12%), Massachusetts Financial Services Co. MA (1.11%) and Northern Trust Corp (0.75%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn.
View institutional ownership trends
.

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BCAB) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -